Solara Active Pharma Sciences closed trading at Rs 415.00, up by 17.35 points or 4.36 per cent from its previous closing of Rs 397.65 on the BSE. The scrip opened at Rs. 397.40 and touched a high and low of Rs 419.65 and Rs 392.45, respectively. So far 10241 shares were traded on the counter. The BSE group 'A' stock of face value of Rs 10 has a 52-week high of Rs 1385.00 and a 52-week low of Rs 323.65.
Allschwil, Switzerland & Radnor, PA, US – May 2, 2022- Idorsia Ltd (SIX: IDIA) & Idorsia Pharmaceuticals, US Inc. today announced that QUVIVIQ™ (daridorexant) CIV 25 mg and 50 mg tablets are now commercially available for adult patients with insomnia, which is characterized by trouble with falling or staying asleep.
Solara Active Pharma Sciences announced that Rajender Juwadi Rao will assume charge as Managing Director & Chief Executive Officer with effect from 01 March 2022. He replaces Bharath R Sesha, who resigned as Managing Director & Chief Executive Officer with effect from 28 February March 2022.
New Delhi: Shares of Solara Active Pharma Sciences continued to bleed on Friday as the selling pressure in the counter sustained following a flop show in the December 2021 quarter
Net profit of Solara Active Pharma Sciences rose 59.09% to Rs 65.80 crore in the quarter ended December 2020 as against Rs 41.36 crore during the previous quarter ended December 2019. Sales rose 24.15% to Rs 426.69 crore in the quarter ended December 2020 as against Rs 343.68 crore during the previous quarter ended December 2019. ParticularsQuarter EndedDec. 2020Dec. 2019% Var.Sales426.69343.68 24 OPM %24.6922.60 -PBDT93.1865.17 43 PBT65.7941.33 59 NP65.8041.36 59
Solara Active Pharma Sciences Limited on Health Canada Inspection List
Engineering company Greaves Cotton, Pharmaceutical firm Solara Active Pharma and Rajesh Exports were the top three performers on the first day of 2022.
ISGEC Heavy Engineering Ltd, Vindhya Telelinks Ltd, VRL Logistics Ltd and Clariant Chemicals (India) Ltd are among the other losers in the BSE's 'A' group today, 12 November 2021.
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story stocks' without revenue, let alone profit. But as Peter Lynch said in One Up On Wall Street, 'Long shots almost never pay off.'
Last week, we had written about how the demerger of Suven Pharmaceuticals had generated phenomenal returns for investors. Another company which has generated healthy returns for its shareholders through the demerger route has been Solara Active Pharma Sciences (Solara). Solara was formed through merger of the API (active pharmaceutical ingredients) business of Strides Pharma and the human API...